Background
Teplizumab is a humanized IgG1 kappa CD3-directed monoclonal antibody used to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D.
Product Details
| Reactivity | Human |
| Specificity | Detects human CD3 in direct ELISA. This non-therapeutic antibody uses the same variable region sequences (VH, VL) as the therapeutic antibody Teplizumab. This product is for research use only. |
| Source | Recombinant Monoclonal Human IgG1 Clone #FB015 |
| Purification | Protein A/G purified from CHO cell culture supernatant |
| Immunogen | Human CD3 |
| Endotoxin Level | <0.10 EU per 1 µg of the antibody by the LAL method |
| Formulation | 0.2 µm filtered solution in PBS |
| Applications | • Flow Cytometry: 0.25 µg/106 cells |
| Reconstitution | Reconstitute at 0.5 mg/ml in sterile 1xPBS |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at -20 to -70°C |
| Storage Conditions | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. • 12 months from the date of receipt at -20 to -70°C as supplied. • 1 month at 2 to 8°C under sterile conditions |